EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
In which stage of an EBV-infection is a selective reduction of immunosuppressive medication reasonable to minimize the risk for PTLD, without putting the transplant recipient at risk of acute rejection episodes due to under immunosuppression?
Aim of study:
Identification of patients at high-risk for PTLD.
Epstein-Barr Virus Infections
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Surveillance of EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients - a Multicenter Prospective Study|
- EB viral load, serology and EBV-specific T cell in pediatric (and adult) renal transplant recipients with or without clinical symptoms of EBV, PTLD etc. [ Time Frame: 9 years ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
|Study Start Date:||July 2003|
|Study Completion Date:||August 2010|
|Primary Completion Date:||August 2010 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00963248
|Heidelberg, Germany, 69120|
|Principal Investigator:||Burkhard Toenshoff, MD, PhD||University Children's Hospital of Heidelberg|